DK120387A - Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling - Google Patents

Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling

Info

Publication number
DK120387A
DK120387A DK120387A DK120387A DK120387A DK 120387 A DK120387 A DK 120387A DK 120387 A DK120387 A DK 120387A DK 120387 A DK120387 A DK 120387A DK 120387 A DK120387 A DK 120387A
Authority
DK
Denmark
Prior art keywords
novel
interferons
preparation
hybrid
omega
Prior art date
Application number
DK120387A
Other languages
Danish (da)
English (en)
Other versions
DK120387D0 (da
Inventor
Rudolf Hauptmann
Peter Swetly
Peter Meindl
Guenther Adolf
Edgar Falkner
Gerhard Bodo
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of DK120387D0 publication Critical patent/DK120387D0/da
Publication of DK120387A publication Critical patent/DK120387A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249Interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Soft Magnetic Materials (AREA)
  • Saccharide Compounds (AREA)
DK120387A 1986-03-10 1987-03-09 Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling DK120387A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863607835 DE3607835A1 (de) 1986-03-10 1986-03-10 Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
DK120387D0 DK120387D0 (da) 1987-03-09
DK120387A true DK120387A (da) 1987-09-11

Family

ID=6295926

Family Applications (1)

Application Number Title Priority Date Filing Date
DK120387A DK120387A (da) 1986-03-10 1987-03-09 Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling

Country Status (21)

Country Link
US (1) US4917887A (fi)
EP (1) EP0236920B1 (fi)
JP (1) JPS62282595A (fi)
KR (1) KR950008191B1 (fi)
AT (1) ATE81671T1 (fi)
AU (1) AU600702B2 (fi)
DD (2) DD276493A5 (fi)
DE (2) DE3607835A1 (fi)
DK (1) DK120387A (fi)
ES (1) ES2052502T3 (fi)
FI (2) FI871012A (fi)
GR (1) GR3006844T3 (fi)
HU (1) HU206896B (fi)
IE (2) IE60573B1 (fi)
IL (1) IL81832A0 (fi)
NO (1) NO870967L (fi)
NZ (1) NZ219549A (fi)
PH (1) PH27060A (fi)
PT (1) PT84427B (fi)
SU (1) SU1604164A3 (fi)
ZA (1) ZA871679B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
AT389318B (de) * 1987-10-22 1989-11-27 Boehringer Ingelheim Int Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
US5000940A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Devices, compositions and the like having or containing an inorganic pyrophosphate
US5047231A (en) * 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
US5000943A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Canine biscuits containing an inorganic pyrophosphate
US5000973A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Nutritionally-balanced canine biscuits containing an inorganic pyrophosphate
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO1999026663A2 (en) 1997-11-20 1999-06-03 Vical, Inc. Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
EP1062337B1 (en) * 1998-03-13 2011-11-09 Brown University Research Foundation Human n-type calcium channel isoform and uses thereof
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CN1568369A (zh) * 2001-08-12 2005-01-19 派普根公司 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6466904B2 (ja) * 2013-03-15 2019-02-06 ヤンセン バイオテツク,インコーポレーテツド インターフェロンアルファ及びオメガ抗体アンタゴニスト
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
JPH064673B2 (ja) * 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
AU1155083A (en) * 1982-01-19 1983-07-28 Cetus Corporation Multiclass hybrid interferons
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
DE3428370A1 (de) * 1984-08-01 1986-02-13 Boehringer Ingelheim International GmbH, 6507 Ingelheim Interferon, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen
DE3584198D1 (de) * 1984-08-01 1991-10-31 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
ATE47864T1 (de) * 1984-08-27 1989-11-15 Genentech Inc Verschiedenartige familie von menschlichen leukozyten-interferonen, zusammensetzungen, die diese enthalten, verfahren zu ihrer herstellung, sowie dna und transfektierte wirte hierfuer.
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators

Also Published As

Publication number Publication date
NO870967L (no) 1987-09-11
NO870967D0 (no) 1987-03-09
AU600702B2 (en) 1990-08-23
NZ219549A (en) 1990-07-26
PH27060A (en) 1993-02-01
EP0236920A3 (en) 1988-03-02
IE870591L (en) 1987-09-10
FI925631A0 (fi) 1992-12-11
IL81832A0 (en) 1987-10-20
DD276493A5 (de) 1990-02-28
EP0236920B1 (de) 1992-10-21
ATE81671T1 (de) 1992-11-15
KR950008191B1 (ko) 1995-07-26
IE60573B1 (en) 1994-07-27
AU6978687A (en) 1987-09-17
FI871012A0 (fi) 1987-03-09
ZA871679B (en) 1988-11-30
DD266118A5 (de) 1989-03-22
DK120387D0 (da) 1987-03-09
PT84427B (pt) 1989-10-04
DE3607835A1 (de) 1987-09-24
FI925631A (fi) 1992-12-11
KR870009020A (ko) 1987-10-22
JPS62282595A (ja) 1987-12-08
FI871012A (fi) 1987-09-11
DE3782259D1 (de) 1992-11-26
HU206896B (en) 1993-01-28
EP0236920A2 (de) 1987-09-16
IE940131L (en) 1987-09-10
HUT44074A (en) 1988-01-28
SU1604164A3 (ru) 1990-10-30
US4917887A (en) 1990-04-17
ES2052502T3 (es) 1994-07-16
PT84427A (de) 1987-04-01
GR3006844T3 (fi) 1993-06-30

Similar Documents

Publication Publication Date Title
DK120387D0 (da) Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling
ES521418A0 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
BR1101088A (pt) Proteìna g do vìrus sincicial respiratório não glicosilada isolada e substancialmente pura
DE68924162D1 (de) Stressproteine und verwendungen dafür.
DK576782A (da) Bicycliske aminosyrer, fremgangsmaader og mellemprodukter til deres fremstilling og deres anvendelse
FI864427A0 (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
DE69428214D1 (de) Transformierender wachstumsfaktor alpha h1
DK193187A (da) Interferoninduceret humanprotein paa ren form, dets fremstilling og anvendlese
DK580886A (da) Dna-sekvens
NO177536C (no) HIV-1-relaterte polypeptider, preparat som omfatter en blanding med minst to polypeptider, samt diagnostisk system og anvendelse av et polypeptid for måling av anti-HIV-1-antistoffer
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi
DK652889D0 (da) Fremgangsmaade til fremstilling af et protein eller polypeptid

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment